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Recent studies demonstrate that alternative splicing of mRNA from a single gene can produce 
two forms of vascular cell adhesion molecule 1 (VCAM-1):  a six-immunoglobulin (Ig) domain 
form (VCAM-6D) and a seven-Ig domain form (VCAM-7D).  Using a COS cell transient expression 
assay, we investigated whether VCAM-6D and VCAM-7D differ functionally in adhesion to 
the integrin VLA-4 (CD49d/CD29) on lymphoid cells. Binding of lymphoid cell lines and peripheral 
blood lymphocytes was completely blocked by VLA-4 monoclonal antibody (mAb) and one 
VCAM-1 mAb (4B9) to both VCAM-6D and VCAM-7D, whereas one VCAM-1 mAb (E1/6) 
completely blocked binding to VCAM-6D but only partially inhibited binding to VCAM-TD. 
We conclude that there is one VLA-4 binding site in the six Ig domains shared between VCAM- 
6D and VCAM-7D, and that the alternatively spliced domain 4 present in VCAM-7D provides 
a second VLA-4 binding site that is blocked by 4B9 but not the E1/6 mAb. We compared the 
inhibitory effects of anti-VCAM-1 and anti-VLA-4 mAbs on lymphoid cell adhesion to cultured 
human umbilical vein endothelial cells (HUVEC).  The anti-VCAM-1  mAb 4B9 blocked the 
binding of PBL and lymphoid tumor cells to stimulated HUVEC better than the anti-VCAM-1 
mAb E1/6. Because VCAM-7D is the predominant form of VCAM-1 expressed by stimulated 
endothelial cells, this difference in VCAM-1 mAb inhibition is attributed to lymphoid cell binding 
to VCAM-7D on stimulated HUVEC. Although the anti-VLA-4 mAb and anti-VCAM-1 mAb 
4B9 equally inhibited PBL binding to stimulated HUVEC, mAb 4B9 inhibited the binding of 
two lymphoid cell lines significantly less than anti-VLA-4 mAb. Combination of 4B9 mAb with 
function-blocking antiserum to human fibronectin, a second known ligand for VLA-4, also failed 
to inhibit as much as anti-VLA-4 mAb. These findings suggest that adhesion of lymphoid cell 
lines through VLA-4 or other c~4 integrins may involve inducible counter-receptor(s) on endothelium 
distinct from either VCAM-1 or fibronectin. Time course experiments indicate that the fraction 
of a4 integrin-dependent binding that can be blocked by anti-VCAM-1  mAb E1/6 rises and 
peaks within 2 h of tumor necrosis factor (TNF) stimulation. We suggest that the binding site 
shared between VCAM-6D and -7D is important soon after TNF stimulation, but that domain 
4 of VCAM-7D or potentially other non-VCAM-1  counter-receptors are sufficient to mediate 
most lymphoid cell adhesion at later time points. 
M 
olecular interactions between the surfaces of lympho- 
cytes and endothelial cells play a critical  role in the 
extravasation  of lymphocytes from the blood stream (1, 2). 
Studies from this (3, 4) and other laboratories  (5, 6) demon- 
strate that two members of the integrin family of cell surface 
heterodimers (LFA-1 and very late activation antigen 4 [VLA- 
4]) 1 mediate distinct mechanisms for lymphocyte-endothe- 
lial cell adhesion. LFA-1, whose expression is limited to leu- 
1 Abbreviations used in this paper: HUVEC, human umbilical vein cord 
endothelial cells; ICAM, intercellular adhesion molecule; VCAM, vascular 
cell adhesion molecule; VLA, very late antigen. 
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or to ICAM-2 on the surface of stimulated or unstimulated 
endothelial cells (1). ICAM-1 expression by endothelial cells 
in culture is substantially upregulated after stimulation by 
proinflammatory cytokines such as TNF, II-1, or INF-'), (3, 
7).  ICAM-2 expression  is constitutively high in vitro and 
not upregulated by cytokines (4, 8). ICAM-1 and ICAM-2 
are  also  constitutively expressed  by PBL,  with  ICAM-1 
showing a significant increase in expression after cell activa- 
tion (4). Interactions between LFA-1 and its counter-receptors 
have been implicated in a number of lymphocyte functions, 
including CTL killing, delivery of T cell help, B lymphocyte 
responses, and graft rejection, as well as the adherence of lym- 
phocytes and neutrophils to endothelial cells, fibroblasts, or 
epithelial cells (1., 9-11). 
The integrin VLA-4, which contains the cr  (CD49d) 
subunit noncovalently associated with the ~/1 (CD29) subunit, 
is expressed by lymphocytes, monocytes, and neural crest-de- 
rived cells, and can interact with vascular cell adhesion mole- 
cule 1 (VCAM-1) (5). Like ICAM-1 and ICAM-2, VCAM-1 
is a member of the Ig superfamily (12), but unlike the ICAMs, 
VCAM-1 is not expressed by lymphocytes (13, 14). VCAM-1 
expression is very low or absent on resting endothelial cells 
in culture but can be induced by cytokines such as TNF or 
II.-1 with kinetics of induction similar but not identical to 
that of ICAM-1 (13, 15). Peak expression of VCAM-1 after 
continuous treatment of endothelial cells with TNF in cul- 
ture occurs  somewhat earlier  than the peak expression  of 
ICAM-1, but both persist at levels substantially higher than 
basal expression for at least 48 h (15). Unlike LFA-1, how- 
ever, VLA-4 can also interact with fibronectin, binding to 
the alternatively spliced CS-1 region located COOH terminal 
to the RGD site of fibronectin recognized by the integrin 
VLA-5 (16-18).  VLA-4 and its counter-receptors have been 
implicated in a number of physiologic and pathophysiologic 
processes in addition to lymphocyte-endothelial cell adhe- 
sion, including cytotoxic T cell killing (19), lymphopoiesis 
(20-23), germinal center development (24), tumor metastasis 
(25, 26), atherogenesis (27), and acute graft rejection (28). 
Recent  studies  have  demonstrated  that  two  different 
VCAM-1 precursors can be produced by alternative mRNA 
splicing  (29-32).  The  original  VCAM-1  cDNA  clone, 
identified from IL-l-stimulated human umbilical vein cord 
endothelial cells (HUVEC) by a functional expression cloning 
strategy,  encodes a  transmembrane glycoprotein with  six 
predicted Ig-like domains (VCAM-6D) (12). Several subse- 
quently identified VCAM-1. cDNA clones, which were pro- 
duced from stimulated HUVEC using PCR, differ from the 
original clone by containing a 276-bp insert at nucleotide 
1034 of the originally published sequence (30-32). This in- 
sert is predicted to encode an additional Ig-like domain after 
the first three domains of VCAM-1, suggesting a seven-domain 
form of VCAM-1 (VCAM-7D). The predicted amino acid 
sequence of the inserted domain (designated domain 4, with 
the following domains redesignated domains 5, 6, and 7) is 
73%  identical with that of the NH2-terminal domain 1. 
There is also high sequence identity between domains 2 and 
5 (60%) and 3 and 6 (58%), but other pairwise comparisons 
show much less identity, suggesting that a three-domain 
module was tandemly duplicated to give rise to domains 1-3 
and 4-6. Messenger KNA for both VCAM-6D and VCAM- 
7D have been identified in stimulated HUVEC, although the 
seven-domain form has been found to be predominant (31, 
32). The two forms of VCAM-1 mKNA most likely repre- 
sent  alternatively  spliced  products of the  same precursor 
mRNA. Sequence ofa genomic VCAM-1 clone indicates that 
domain 4 corresponds to a single exon located between the 
exons encoding domains 3 and 5 (29). 
There is increasing evidence for multiple ligand recogni- 
tion by integrins. LFA-1, for example, interacts with ICAM-1 
and ICAM-2 (1). Recently, a functional comparison of anti- 
LFA-1 mAb vs. a cocktail of anti-ICAM-1 and anti-ICAM-2 
mAbs has led to the identification of a third LFA-1 ligand, 
ICAM-3 (4, 33). Although VLA-4 has been shown to bind 
to fibronectin and VCAM-1, it is not known whether VLA-4 
interacts differentially with the two alternatively spliced forms 
of VCAM-1 or whether VLA-4 interacts with other ligand(s) 
completely distinct from VCAM-1. In experiments reported 
here, we compared the adhesion of PBL and lymphoid tumor 
lines to VCAM-6D vs. VCAM-7D. Our results show that 
both VCAM-6D and VCAM-7D support VLA-4-dependent 
adhesion of lymphoid cells, but that based on mAb blocking 
studies, adhesion to VCAM-7D involves one epitope shared 
with VCAM-6D and another epitope involving the alterna- 
tively spliced domain 4 found in VCAM-7D. We also assessed 
adhesion of PBL and lymphoid cell lines to stimulated and 
unstimulated HUVEC and compared the inhibitory effects 
of anti-VLA-4 and anti-VCAM-1 mAbs. Antifibronectin an- 
tiserum was also studied to assess the role of fibronectin in 
lymphocyte-endothelial  cell interactions. Our findings in the 
HUVEC system are consistent not only with the adhesion 
of lymphoid cells via two distinct VLA-4 binding sites on 
VCAM-1, but in the case of cell line adhesion to HUVEC, 
also provide evidence for an inducible or4 integrin counter- 
receptor distinct from VCAM-7D, VCAM-6D, or fibronectin. 
Materials and Methods 
Cell Culture.  HUVEC were purchased from Clonetics Corp. 
(San Diego, CA) and maintained for up to six doublings in M199 
media with 20% fetal bovine low endotoxin-defined serum (Hy- 
Clone Laboratories, Logan, UT), 100/~g/ml bovine endothelial 
cell growth supplement  (Biomedical  Technologies,  Stoughton, MA), 
100/zg/ml heparin, 20 mM Hepes, 5 mM glutamine, and 50 ~g/ml 
gentamicin. Tissue culture surfaces were pretreated with 1 ~g/cm  2 
of human plasma fibronectin in HBSS for 30 min at 37~  to pro- 
mote endothelial cell attachment. Human lymphocytic cell lines 
and SV-40-transformed  African green money kidney cells (COS) 
were maintained in complete media  (RPMI 1640 with 10% FCS, 
5 mM glutamine, and 50 ~g/ml gentamicin). Peripheral mono- 
nuclear cells were obtained by dextran sedimentation and Ficoll- 
Hypaque (1.077) centrifugation. PBL were enriched by incubating 
mononuclear  ceils in complete media on tissue  culture plastic twice 
for 45 min at 37~ 
Antibodies.  Mouse  anti-human mAbs used were TS1/22 (anti- 
LFA-1) (34), HP2/1 (anti-VLA-4) (35), 4B9 (anti-VCAM-1) (15), 
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at concentrations  10-fold greater than required to give maximal 
inhibition of function: 1:250 dilution of TS1/22 ascites, 40 #g/ml 
of purified HP2/1, 40 #g/ml of purified 4B9, and neat tissue cul- 
ture supematant of E1/6. The concentration of  El/6 was both 10- 
fold higher than the saturation concentration determined from flow 
cytometry  of labeled stimulated HUVEC as well as 10-fold higher 
than that required to achieve maximum inhibition of Ramos cell 
adhesion to TNF-stimulated HUVEC. More than 75% of  HUVEC 
stimulated with 25 ng/ml TNF for 24 h were positive for E1/6. 
Affinity-purified goat antiserum to human fibronectin was from 
Sigma Chemical Co.  (St. Louis, MO). 
Transfeaed COS Cell ~  Assa~  Purified  eDNA of  VCAM-1 
clones 41 (VCAM-6D) and 1Ell (VCAM-7D) in the transient ex- 
pression vector CDM8 (32) were digested with each of the restric- 
tion enzymes Xho I, Bsu36 I, and Aft III (New England Biolabs, 
Beverly, MA) to confirm that the two clones corresponded to six- 
and seven-domain  forms ofVCAM-1. Immunoprecipitation of  trans- 
fected cell lysates with the anti-VCAM-1 mAb 4B9 confirms that 
these  cDNAs correspond  to VCAM-6D  and  VCAM-TD  (32). 
Purified cDNA of  VCAM-6D or VCAM-7D in CDMS, or CDM8 
vector alone, were transfected into COS cells using DEAE-dextran 
(4-5  #g plasmid  per  10-cm plate  of COS  cells at  50%-60% 
confluence) (36). COS cells were suspended using trypsin-EDTA 
2 d after infection and reseeded at "~10 COS celis/mm s. 3 d after 
transfection,  COS  cells were  washed  three  times  with  1% 
FCS/tLPMI at 25~  and in some cases, preincubated for 15 min 
with mAb 4B9 or E1/6. PBL or lymphoid tumor cells in  1% 
FCS/RPMI were labeled with the carboxyfluorescein compound 
2'-7'-bis-(-2-carboxyetbyl)-5(and-6) carboxyfluorescein,  acetoxy- 
methyl ester (BCECF-AM; Molecular Probes Inc., Eugene, OK) 
(10 #g/m1,  diluted  from stock  in  DMSO;  20 rain  at  37~ 
resuspended in 1% FCS/KPMI, and in some cases, preincubated 
with mAb HF2/1 for 15 rain at 25~  Labeled  lymphoid cells  were 
added at 2  x  10Vmm  2 and allowed to settle and adhere for 10 
min at 25~  Nonadherent cells were removed by five washes using 
1% FCS/P,  PMI. 
For each experiment, bound cells  were quantified using a fluores- 
cence microscope to score the number of lymphoid cells in 5-10 
100x  fields (12-24 mm2). COS calls were removed from each 
plate using 5 mM EDTA in HBSS to calcuhte the number of COS 
cells/mm 2.  The  numbers  of  VCAM-l-transfected  and  vector 
only-transfected COS cells/ram  s were within <10% of each other. 
COS cell transfection efficiency was determined as described (4) 
by flow cytometric analysis of COS cells stained with the anti- 
VCAM-1 mAb E1/6 or the nonbinding  mAb X63. Transfection 
efficiency ranged  from 20 to  53%  (mean 32%).  Binding  was 
quantified as: cells bound/transfected COS cell =  (cells bound to 
VCAM-l-transfectants/mmS-cells  bound  to  CDM8-transfec- 
tants/mm~)/[(COS cdls/mm 2)  ￿  (VCAM-1 tmsfection dticiency)]. 
HUVEC Adhesion Assay.  PBL or lymphoid tumor cells  in com- 
plete media/20 mM Hepes were labeled with BCECF-AM and 
resuspended in complete media/20 mM Hepes. Lymphoid cells  were 
preincubated with one or more mAbs for 30 rain at 37~  or with 
medium alone. HUVEC were grown to confluence  in 96-well tissue 
culture plates and incubated for 0-24 h at 37~  with 25 ng/ml 
of recombinant human TNFol (Genzyme, Boston, MA). Before 
testing cell line adhesion, HUVEC monolayers were washed three 
times with complete media/20 mM Hepes, and to some wells, mAbs 
and/or diluted  antiserum  were added for 30 min at 37~  5% 
COs. Lymphoid cells (10S/well) were overhyed on HUVEC and 
allowed to settle and adhere for 30 min at 37~  5% COs. To re- 
move nonadherent cells, wells were washed five times by aspirating 
with a 21-gange needle and adding 100 #1 of complete media/20 
mM Hepes. Percent adherence was determined using a fluorescence 
concentration analyzer (Pandex Laboratories, Inc., Mundelein, 1L) 
by comparing the residual fluorescence  concentrations in each well 
to the input fluorescence concentration. 
Fibronectin  Adhesion Assay.  Nontissue culture 96-well  phtes were 
incubated with 5 ~g/ml of human plasma fibronectin (New York 
Blood Center, New York) in 100 mM NaHCO3 for 2 h at 37~ 
and then with 1% heat-treated (30 min, 56~  BSA in P,  PMI 1640 
for 1 h at 37~  Diluted antiserum or mAbs were added to some 
wells for 30 min at 37~  Lymphoid  ceils  were hbeled with BCECF- 
AM, resuspended in 1% BSA/R.PMI, and in some cases, prein- 
cubated with a mAb for 30 min at 37~  Labeled lymphoid cells 
were added at I0  s cells/well and allowed to settle and adhere for 
30  min  at  37~  5%  CO2.  Unbound cells were  removed by 
washing five times with 1% BSA/KPMI, and percent adherence 
was determined using a fluorescence concentration  analyzer. 
Results 
Lymphoid Cell Binding to COS Cells Expressing  VCAM-6D 
or VCAM-7L~  To test whether the two alternatively spliced 
forms of VCAM-1 differ functionally, we assayed the adhe- 
sion of PBL and two lymphoid cells lines to COS cells trans- 
fected with either VCAM-6D  or VCAM-7D cDNA.  The 
inhibitory effects of the anti-VLA-4 mAb HP2/1 and the anti- 
VCAM-1 mAbs 4B9 and E1/6 were compared. Transfected 
COS cells expressed VCAM-6D and VCAM-TD at roughly 
the same level, as demonstrated by flow cytometric analysis 
using the anti-VCAM-1 mAb E1/6 (Fig. 1). PBL bound well 
to COS cells expressing either form of VCAM-1,  forming 
rosettes of at least 20 cells per transfected COS cell (Fig. 2 
A). Two lymphocytic cells lines (gamos [B call origin] and 
SKW3 IT call origin] also bound well to VCAM-1 transfec- 
rants, forming rosettes of at least 10 cells per transfected COS 
cell (Fig. 2, B and C). Binding of PBL or either of the ceU 
lines to COS ceUs transfected with the CDM8 vector alone 
was 5-10-fold less than binding to VCAM-6D or VCAM-7D 
transfectants. 
PBL or cell line binding to VCAM-6D- or VCAM-7D- 
transfected COS cells was strictly VLA-4 dependent, as demon- 
CONTROL  mAb E1/6 
VCAM-6D L  TRANSFECTANTS 
i  i  "U  '  '  i 
VCAM-7D L~  TRANSFECTANIS 
~o  loo 
Figure 1. 
VCAM-7D or VCAM-6D. Transfected  COS cells were  hbded with non- 
binding control mAb X63 or the anti-VCAM-1 mAb E1/6. 
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Figure 2.  Binding of (A) PBL, 
(/3) P,  arnos, or (C) SKW3 cells to 
COS cells exln~ssing VCAM-6D or 
VCAM-7D. The mean fluorescence 
channel was 104 +  9 (+1 SD) for 
VCAM-6D expression and 115  _+ 
10  for  VCAM-7D  expression  as 
determined  by  flow  cytometry. 
Background binding to vector only- 
transfected COS cells was 8-25% 
(mean  14%)  of  the  binding  to 
VCAM-6D- or  VCAM-7D-transfec- 
ted COS celh in the presence of con- 
trol medium. Error bars represent 
1 SD of the mean of two PBL, four 
Ramos,  and three SKW3 experi- 
ments. 
strated by the abolition of binding after preincubation with 
the anti-VLA-4 mAb HP2/1 (Fig. 2). The anti-VCAM-1 mAb 
4B9  also  completely blocked PBL or cell line binding to 
VCAM-6D or VCAM-TD transfectants. In contrast,  prein- 
cubation  with  the  anti-VCAM-1  mAb  El/6  completdy 
blocked PBL or cell line binding to VCAM-6D-transfected 
COS cells,  but only partially blocked binding to VCAM- 
7D-transfected COS ceils (PBL by an average of 40%, gamos 
by 30%, and SKW3 by 60%). Thus, V'LA-4-dependent adhe- 
100- 
80" 
60" 
40' 
20' 
0 
Medium  TS1/22 
Figure  3.  JY  cell binding to 
24-h TNP-stimulated  HUVEC. 
Before binding, JY cells were in- 
cubated with control medium or 
with mAb TS1/22 (anti-LFA-1). 
R~sults are from one experiment 
with error bars indicating 1 SD 
of four replicates. 
sion to VCAM-6D involved one binding site dependent on 
the epitope recognized by mAb E1/6; VCAM-7D expressed 
a second VLA-4 binding site that neither was shared with 
VCAM-6D  nor functionally inhibited by mAb E1/6. 
VLA-4-dependent  Adhesion of  Lymphocytic Cell Lines to TNlZ 
stimulated and UnstimulatedHUVEC  The anti-V'LA-4 mAb 
HP2/1 and the anti-VCAM-1 mAbs 4139 and E1/6 were com- 
pared for their abilities to inhibit the adhesion of PBL, gamos, 
or SKW3  cells  to unstimulated HUVEC  or  to  HUVEC 
stimulated for 24 h with TNF. To block interactions between 
LFA-1 and endothelial ICAM-1 or ICAM-2, lymphoid calls 
were preincubated with the anti-LFA-1 mAb TS1/22. This 
mAb  was  confirmed  as  a  functional inhibitor  of LFA-1- 
dependent adhesion by preincubating the B lymphocytic cell 
line JY with mAb TS1/22 and demonstrating a >85% inhi- 
bition of JY calls binding to 24-h TNF-stimulated HUVEC 
(Fig.  3 and reference 3). JY cells express LFA-1 but little if 
any of the VLA-4 CD29 ~  subunit (37). 
Preincubation  with TS1/22  alone  inhibited the binding 
of Kamos or SKW3 cells  to TNF-stimulated HUVEC by 
<10%  compared  with preincubation with medium alone; 
TS1/22  inhibited PBL  binding by <20%  compared  with 
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were preincubated with the anti-VLA-4 mAb HP2/1 in ad- 
dition to TS1/22, binding to TNF-stimulated HUVEC was 
significantly inhibited compared with binding after incuba- 
tion with medium alone (Fig. 4). Adhesion of PBL to TNF- 
stimulated HUVEC was blocked by 55%, Ramos cells by 
85%, and SKW3 cells by 60%. 
Preincubation of TNF-stimulated HUVEC with the anti- 
VCAM-1 4119 (in addition to lymphoid cell prdncubation 
with TS1/22) blocked binding of PBL equally as well as prein- 
cubation with HP2/1 and TS1/22 (Fig. 4 A). In contrast, 
the anti-VCAM-1 mAb E1/6 blocked binding of PBL to TNF- 
stimulated HUVEC by only a fraction of that observed after 
preincubation with HP2/1 and TS1/22, or 4139 and TS1/22. 
For Ramos or SKW3 cells (Fig. 4, B and C), preincubation 
of TNF-stimulated HUVEC with either 4B9 or E1/6 (in 
addition to cell line preincubation with TS1/22) failed to block 
binding as well as HP2/1 and TS1/22. For each cell line, how- 
ever, inhibition with 4B9 was significantly greater than that 
with El/6. 
For each cell type tested, adhesion to unstimulated HUVEC 
was  substantially  less  than  adhesion  to  TNF-stimulated 
HUVEC (Fig. 4). Preincubation with TS1/22 alone modestly 
but significantly inhibited adhesion of PBL and SKW3 cells 
to unstimulated HUVEC; TS1/22 did not inhibit binding 
of Ramos cells to unstimulated HU3/EC. When PBL, Ramos, 
or SKW3 cells were preincubated with HP2/1 in addition 
to TS1/22, only slight further inhibition in binding was ob- 
served,  indicating that VLA-4 counter-receptor(s) on en- 
dothelium are cytokine inducible. Basal cell line adhesion to 
unstimulated HUVEC was not affected by additionally prein- 
cubating HUVEC with anti-VCAM-1  mAb 4B9 or E1/6 
(Fig. 4). 
A Ligand on Stimulated Endothelium Distinct  from VCAM-1 
and Fibronectin.  The two cell lines we examined, but not 
PBL, bound to stimulated endothelium through a pathway 
that was blocked by mAb to the VLA-4 c~ subunit but not 
by 4B9 mAb to VCAM-1. These mAbs completely blocked 
binding of the same cells to COS cells expressing VCAM-1. 
Because VLA-4 can bind to an alternatively  spliced form of 
fibronectin (16, 17), we assessed whether antifibronectin an- 
tiserum could block cell line binding to TNF-stimulated 
HUVEC. To demonstrate antifibronectin antiserum as an in- 
hibitor of lymphocyte-fibronectin adhesion, we determined 
the binding of Ramos and SKW3 cells to purified plasma 
fibronectin absorbed onto plastic microtiter phtes at 5 #g/ml. 
For both cell lines, binding to purified fibronectin was com- 
pletdy inhibited by preincubation of the plates with antiserum 
to human fibronectin (Fig. 5 A). Cell line preincubation with 
the anti-VLA-4 mAb HP2/1 also completely  blocked binding 
to fibronectin, whereas preincubation with the anti-LFA-1 
mAb TS1/22 had no effect. Cell line binding to BSA was 
minimal (Fig.  5 A).  Neither Ramos nor SKW3  express 
VLA-5, as determined by flow cytometric analysis (data not 
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Figure 4.  Binding of (A) PBL, 
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binding to (,4) fibronectin coated on 
plastic or (B) 24-h TNF-stimuhted 
HUVEC. Error bars represent 1 SD 
of the mean of three experiments 
performed in quadruplicate. 
shown).  This result therefore confirms previous reports of 
VLA-4-dependent/VLA-5-independent  adhesion of lympho- 
cytes to fibronectin  (16, 17). 
Preincubation  of 24-h  TNF-stimulated HUVEC  with 
antifibronectin antiserum (in addition to cell line preincuba- 
tion with the anti-LFA-1 mAb TS1/22) inhibited Ramos cell 
adhesion by <20% and SKW3 cell adhesion by <12% (Fig. 
5 B). When antifibronectin antiserum was used in combina- 
tion with anti-VCAM-1 mAb 4B9 or E1/6,  no or only a 
moderate additive effect on the inhibition of adhesion to TNF- 
stimulated  HUVEC  was  observed  (additional  inhibition 
<8%) (Fig. 5 B). Inhibition remained substantially less than 
that obtained with VLA-4 mAb. These results suggest that 
cell lines express an integrin containing the VLA-4 ot subunit 
that can recognize a ligand on stimulated endothelium that 
is distinct  from VCAM-1 and fibronectin. 
Induction of E1/6-dependent/VLA-4-dependent Ramos Cell 
Adhesion to TNF-stimulated  HUVEC.  To determine the in- 
duction of E1/6-dependent adhesion of lymphoid cells to 
HUVEC, we assessed Ramos cell binding to HUVEC after 
0, 2, 3.5, or 7 h of TNF stimulation.  HUVEC used for any 
one experiment were from a single umbilical cord. VLA-4- 
dependent adhesion was calculated  as the percentage of Ramos 
cell binding that was blocked by anti-VLA-4 mAb HP2/1 
in the presence of anti-LFA-1 mAb TS1/22.  For five experi- 
ments, VLA-4-dependent adhesion increased as the time of 
TNF  stimulation increased (Fig. 6),  consistent  with  the 
cytokine inducibility  of VLA-4 counter-receptor(s)  on en- 
dothelium. There was no significant VLA-4-dependent adhe- 
sion to unstimulated HUVEC. 
VLA-4-dependent adhesion that could be blocked by E1/6 
in the presence of anti-LFA-1 mAb TS1/22  was character- 
ized as E1/6 dependent. Results from five  experiments showed 
that after 2 h of TNF stimulation, the majority of VLA-4- 
dependent binding of Ramos cells was E1/6 dependent, but 
after 7 h of stimulation, the majority of VLA-4-dependent 
adhesion was not blocked by E1/6 (Fig. 6). 
Discussion 
The integrin VLA-4 mediates  lymphocyte adhesion  to 
stimulated endothelium by binding to VCAM-1, a member 
of the Ig superfamily whose expression is induced on en- 
dothelium by proinflammatory cytokines (5, 12, 26). At least 
25 "~ 
20 
15- 
I0 o 
5- 
oi  i 
0  8 
￿9  VLA~ 
.... -D---  VLA-4  -dependenl/E I/6-~t 
1  2  3  4  5  6  7 
TNF stimulation (h) 
% cells binding 
mAb  Oh  2h  3.5  h  7h 
TS 1/22 
TS 1/22 + HP2/1 
TS 1/22 + El/6 
8.2 + 1.3  17.7 + 2.3  22.7 + 5.6  26.5 +__.  4.9 
7.1 + 2.3  6.4 + 1.8  6.9 + 2.3  6.0 + 1.7 
9.5 + 3.0  10.2 + 1.8  16.2 + 4.0  23.8 +__. 3.2 
Figure 6.  Comparison of VLA-4-dependent vs. VLA-4-dependent/E1/6- 
dependent adhesion of Ramos ceils to HUVEC as functions of time of 
TNF stimulation. Error bars represent 1 SD of the mean of five experimental 
calculations. The mean of the raw data on which these calculations were 
based are also shown  _+  1  SD. 
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the human VCAM-1 gene as a result of alternative mKNA 
splicing (29). The resulting proteins correspond to a six-Ig 
domain form of VCAM-1 (VCAM-6D) and a seven-Ig do- 
main form (VCAM-7D).  To test whether VCAM-6D and 
VCAM-7D differ functionally in mediating VLA-4-dependent 
adhesion of  lymphoid cells, we transiently  expressed  VCAM-6D 
or VCAM-7D in COS calls and assayed  the adhesion of PBL 
or lymphoid tumor calls. Both PBL and lymphoid tumor 
cells bound well to each form of VCAM-1 in a strict VLA-4- 
dependent fashion. One anti-VCAM-1 mAb, 4B9, abrogated 
binding of  lymphoid cells to either VCAM-6D or VCAM-7D, 
as expected from a previous study (32) using this mAb that 
reported no functional difference between VCAM-6D and 
VCAM-7D. In contrast, we found that a second anti-VCAM-1 
mAb, E1/6, completely blocked binding to VCAM-6D but 
only partially inhibited binding to VCAM-7D. Several  previous 
reports (29, 31, 32) confirm that VCAM-6D and VCAM- 
7D are identical in primary sequence except for an inserted 
Ig domain in VCAM-7D (domain 4). Our findings suggest, 
therefore, that one VLA-4 binding site, which can be blocked 
by mAb E1/6, involves only the six Ig domains shared be- 
tween VCAM-6D and VCAM-TD; the addition of domain 
4 in VCAM-7D provides a second VLA-4 binding site that 
is not blocked by mAb E1/6. 
It is most likely that this second VLA-4 binding site localizes 
specifically to the primary protein sequence of domain 4, al- 
though it remains a formal possibility that the additional ex- 
pression of domain 4 confers a change in conformation that 
reveals a second binding site elsewhere in VCAM-1. Previous 
studies of ICAM-1 argue against this latter explanation (38, 
39); multiple integrin binding sites on ICAM-1 that localize 
to distinct Ig domains were dearly suggested by results from 
experiments using domain deletion mutants and subsequently 
confirmed  by experiments using amino acid substitution mu- 
tants of ICAM-1. Two lines of evidence allow us to predict 
that the VLA-4 binding site blocked by mAb E1/6 and shared 
between VCAM-6D and VCAM-7D localizes to domain 1. 
First, the epitope recognized by E1/6 has recently  been local- 
ized to the three NH2-terminal  domains  of VCAM-1  (do- 
mains 1-3), based on immunostaining of a protein for which 
domains 1-3 were fused to the Fc portion of human IgG1 
(25). mAb E1/6 completely  blocks VLA-4-dependent adhe- 
sion of melanoma cells to this fusion protein.  Second, do- 
main 4 and domain 1 have a much higher degree of amino 
acid identity with each other (73%) than they have with any 
other domain of VCAM-1  (8-23%). 
Previous studies of ICAM-1  (38-40)  provide precedence 
for our findings here that mAbs can differentially inhibit mul- 
tiple integrin binding sites on an Ig-like cellular adhesion mol- 
ecnle. ICAM-1 expresses two integrin binding sites: one in 
domain I for LFA-1 (38) and another in domain 3 for Mac-1 
(40), a sister integrin of  LFA-1 that shares the same/32 subunit. 
Several mAbs whose epitopes map to domain I of ICAM-1 
inhibit ICAM-1 binding to LFA-1 but not Mac-1 (38, 40). 
In contrast, one mAb (K6.5) completely blocks LFA-1 binding 
to domain 1 as well as Mac-1 binding to domain 3 (40). In- 
terestingly, the epitope of mAb R6.5 maps to domain 2 of 
ICAM-1  (38). 
In paralld to studies on transfected COS ceils, we exam- 
ined the inhibitory effects of anti-VCAM-1 and anti-VLA-4 
mAb on PBL and lymphoid tumor ceil adhesion to TNF- 
stimulated or unstimulated HUVEC. The function blocking 
anti-LFA-1 mAb TS1/22 was included in each experiment 
to prevent interactions with endothelial ICAM-1 or ICAM-2. 
For each cell type, the anti-VCAM-1 mAb 4139 inhibited adhe- 
sion significantly better than the anti-VCAM-1 mAb E1/6, 
similar to the pattern of mAbs 4B9 and E1/6 inhibition ob- 
served with lymphoid cell adhesion to VCAM-7D-transfected 
COS cells. Because VCAM-TD is the predominant form of 
VCAM-1 expressed  on well-stimulated HUVEC (such as 24-h 
TNF-stimulated HUVEC) (31, 32), the observed difference 
in inhibition between mAbs 4B9 and E1/6 in the HUVEC 
system most likely  reflects  lymphoid cell adhesion to VCAM-TD. 
Preincubation of HUVEC with mAb E1/6 blocks the VLA-4 
binding site shared between VCAM-6D and VCAM-7D but 
does not block the second binding site on VCAM-7D in- 
volving  domain 4.  The mAb 4B9  blocks  both  sites on 
VCAM-TD. 
Using the HUVEC system, we also directly compared the 
inhibitory effects  of the anti-VLA-4  mAb HP2/1 and the anti- 
VCAM-1 mAb 4B9 to determine whether there might exist 
VLA-4 counter-receptors distinct from VCAM-1. A similar 
strategy of comparing the inhibitory effects of receptor and 
counter-receptor mAbs has been previously used to provide 
evidence for LFA-1 counter-receptors distinct from ICAM-1 
(3, 41, 42), and led to the subsequent identification of ICAM-2 
and ICAM-3 (4,  8,  33).  Here,  we chose mAb HP2/1  to 
VLA-4ot and 4B9 to VCAM-1 for comparison because our 
COS cells experiments showed that either mAb used alone 
completely blocks lymphoid ceil binding to either form of 
VCAM-1.  It has also been shown that mAb HP2/1 corn- 
pletdy blocks two other adhesive  functions of  VLA-4; namely, 
interactions  with  fibronectin  and lymphocyte homotypic 
aggregation (43). In experiments with PBL, mAbs HP2/1 
and 4B9 blocked adhesion to stimulated HUVEC equally well, 
suggesting no use of alternative VLA-4 counter-receptors; 
however, for the two cell lines tested, mAb HP2/1 blocked 
adhesion to stimulated HUVEC significantly  better than mAb 
4B9. When function-blocking antiserum to human fibronectin 
was used in combination with mAb 4B9, inhibition was still 
significantly less than that observed with mAb HP2/1. These 
results provide evidence  for the existence  of counter-receptor(s) 
for an ol4 integrin that are inducible on the surface of en- 
dothdium and are distinct from VCAM-6D, VCAM-7D, and 
fibronectin. Our functional evidence for a pathway of adhe- 
sion of lymphocytic  cell lines to stimulated endothelium that 
is blocked by VLA-4 c~ subunit mAb but not VCAM-1 mAb 
is particularly strong because of  our demonstration that these 
mAbs equally block adhesion of the same cell lines to trans- 
fected COS cells, and adhesion of PBL to stimulated en- 
dothelium. It was similar evidence that ICAM-1 and LFA-1 
mAbs would equally block adhesion of some cell types, but 
that ICAM-1  mAb was less effective than LFA-1 mAb in 
1439  Vonderheide  and Springer blocking other adhesion assays (41), which subsequently led 
to the identification of ICAM-2 and ICAM-3 (4, 33). The 
current studies should stimulate similar efforts, by produc- 
tion of function-blocking  mAbs, or functional done screening 
assays, to identify and definitively characterize alternative cx4 
integrin ligand(s). 
It is not known why the two lymphocytic cell lines were 
found to bind novel ol4 integrin counter-receptor(s) but resting 
PBL were not. There may be differences in the activation 
of o14fll, by  resting PBL  vs.  lymphoid tumor cells  that 
confer variations in function, such as by proteolytic deavage 
of the cx4  subunit  or  cellular  signals  that  regulate c~4fll 
avidity (18, 37, 44, 45).  Alternatively,  the c~4 subunit may 
associate with distinct 13 subunits, such as B7 (46, 47), and 
function with a unique ligand specificity. Curiously, mRNA 
for/37 has been easily detected in some lymphocytic cell lines 
but not in resting peripheral T  cells (47). 
Adhesion to endothelium that is dependent on o~4 inte- 
grin(s) and that is not ascribable to VCAM-1 or fibronectin 
has not been previously suggested. One previous study of 
resting T cell adhesion to stimulated HUVEC found no differ- 
ence in inhibition between the anti-VCAM-1 mAb 4B9 and 
a function-blocking anti-VLA-4 mAb (48), consistent with 
our results  using PBL.  In a study (6) of LFA-l-negative B 
cells obtained from a patient with leukocyte adhesion deficiency 
(49), mAb 4]39 failed to inhibit binding to stimulated HUVEC 
as well as a function-blocking anti-VLA-4 mAb; the differ- 
ence was attributed to lymphocyte  interactions with fibronectin 
on HUVEC,  but this was not  tested with antiserum to 
fibronectin as we have done here. In studies (50, 51) of other 
anti-VCAM-1 mAbs used with various mAbs that block LFA-1 
function, binding of resting T cells to stimulated HUVEC 
was found to be inhibited but not to the same level as binding 
to unstimulated HUVEC in the presence of the same mAbs. 
We obtained similar results using PBL and the anti-VCAM-1 
mAb E1/6. In one study of a lymphocytic  cell line (43), mAbs 
4B9 and HP2/1 inhibited binding to stimulated HUVEC 
equally  well. In another study of cell lines  (15), however, 
binding to stimulated HUVEC after preincubation with 4B9 
and a mAb to LFA-1/3 chain was greater than binding to 
unstimulated HUVEC after  preincubation with the same 
mAb. 
The studies comparing Ramos cell adhesion to HUVEC 
stimulated for various times with TNF provide functional 
evidence that the binding site shared by VCAM-6D and -7D 
is important soon after TNF stimulation. At 2 h of TNF 
stimulation, E1/6-dependent adhesion reached its maximum, 
constituting the majority of the VLA-4-dependent binding. 
VLA-4-dependent binding, however, continued to increase 
with time of stimulation of HUVEC by TNF. This may be 
either because VCAM-6D is expressed earlier than VCAM-7D, 
or if VCAM-6D and VCAM-TD are expressed with similar 
kinetics, because two-site binding is important early on at 
low VCAM-1 cell surface density, whereas later on at higher 
density the alternatively spliced domain 4 is sufficient to give 
ef~cient  binding. VCAM-7D  mRNA is present in much 
higher amounts than VCAM-6D mRNA at all time points 
examined, but VCAM-6D is present in higher amounts at 
2.5 h  than at subsequent time points (32).  Although en- 
dothelial expression of VCAM-6D at the protein level has 
not yet been directly demonstrated, there is good reason to 
expect its expression based on cDNA cloning (12), isolation 
of VCAM-6D mRNA from stimulated HUVEC (31, 32), 
and the expression of VCAM-6D as a mature glycoprotein 
in transfected  cells (32). 
The generation of one vs. two VLA-4 binding sites on 
VCAM-1 represents an alternative mechanism for regulating 
the density of integrin binding sites on the surface of en- 
dothelium. Assuming that like ICAM-1, VCAM-7D is an 
unpaired molecule with Ig domains arranged end to end, size 
considerations suggest that it should  be possible for two VLA-4 
molecules to bind to the same VCAM-7D molecule (1). By 
alternatively  splicing VCAM-1, endothelial cells would be 
able to control the number of VLA-4 binding sites expressed. 
ICAM-1 also expresses two integrin binding sites (one for 
LFA-1 [38] and a second for Mac-1 [39]), but these sites are 
not alternatively  spliced.  Binding of a single vs. multiple 
VLA-4 molecules to VCAM-7D may affect the strength of 
adhesiveness, and may also transmit distinct signals for lym- 
phocyte adhesion to endothelium or for transmigration across 
it. Furthermore, because lymphocytes can modulate the adhe- 
siveness of VLA-4 for its counter-receptors (44, 45), it may 
be possible for such modulation to affect the avidity of VLA-4 
for its two VCAM-1 binding sites differentially.  Understanding 
the interaction of a4 integrin(s) with counter-receptors and 
the regulation of this interaction by both endothelial cells 
and lymphocytes will be important for future endeavors aimed 
at disrupting these adhesion pathways in the clinical manage- 
ment of chronic inflammatory diseases or graft rejection. 
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